gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis

Simple item page
dc.contributor.authorSirgel F.A.
dc.contributor.authorWarren R.M.
dc.contributor.authorStreicher E.M.
dc.contributor.authorVictor T.C.
dc.contributor.authorVan helden P.D.
dc.contributor.authorBottger E.C.
dc.date.accessioned2012-05-17T08:58:55Z
dc.date.available2012-05-17T08:58:55Z
dc.date.issued2012
dc.description.abstractObjectives: To compare mutations in the quinolone resistance-determining region of the gyrA gene and flanking sequences with the MICs of ofloxacin and moxifloxacin for Mycobacterium tuberculosis. Methods: The presence of mutations in 177 drug-resistant M. tuberculosis isolates was determined by DNA sequencing and the MICs quantified by MGIT 960. Results: Single nucleotide polymorphisms were detected at codons 94 (n = 30), 90 (n = 12), 91 (n = 3), 89 (n = 1), 88 (n = 1) and 80 (n = 1). Four isolates with double mutations D94G plus A90V (n = 2) and D94G plus D94N (n = 2) reflect mixed populations. Agreement between genotypic and phenotypic susceptibility was high (≥97%) for both drugs. Mutant isolates had an MIC 50 of 8.0 mg/L and an MIC 90 of >10 mg/L for ofloxacin compared with an MIC 50 and MIC 90 of 2.0 mg/L for moxifloxacin. Codons 94 and 88 were linked to higher levels of fluoroquinolone resistance compared with codons 90, 91 and 89. The MIC distributions for the wild-type isolates ranged from ≤0.5 to 2.0 mg/L for ofloxacin and from ≤0.125 to 0.25 mg/L for moxifloxacin. However, 96% of the isolates with genetic alterations had MICs ≤2.0 mg/L for moxifloxacin, which is within its achievable serum levels. Conclusions: This study provides quantitative evidence that the addition of moxifloxacin to extensively drug-resistant tuberculosis (XDR-TB) regimens based on a clinical breakpoint of 2.0 mg/L has merit. The use of moxifloxacin in the treatment of multidrug-resistant tuberculosis may prevent the acquisition of additional mutations and development of XDR-TB. © The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
dc.identifier.citationJournal of Antimicrobial Chemotherapy
dc.identifier.citation67
dc.identifier.citation5
dc.identifier.citation1088
dc.identifier.citation1093
dc.identifier.issn3057453
dc.identifier.other10.1093/jac/dks033
dc.identifier.urihttp://hdl.handle.net/10019.1/21016
dc.subjectDNA topoisomerase (ATP hydrolysing)
dc.subjectDNA topoisomerase (ATP hydrolysing) A
dc.subjectmoxifloxacin
dc.subjectofloxacin
dc.subjectquinoline derived antiinfective agent
dc.subjectarticle
dc.subjectbacterium isolate
dc.subjectcodon
dc.subjectDNA sequence
dc.subjectgene mutation
dc.subjectgenetic susceptibility
dc.subjectlimit of quantitation
dc.subjectMycobacterium tuberculosis
dc.subjectnonhuman
dc.subjectphenotype
dc.subjectsingle nucleotide polymorphism
dc.subjectwild type
dc.titlegyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Publications